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Decline in C-Reactive Protein After Successful Ablation of Long-Lasting
Fibrillationo the Editor: Increased levels of C-reactive protein (CRP) have
een demonstrated to be an independent predictor of atrial fibrillation
AF) and to correlate with AF burden (1,2). In addition, inflam-
ation and endothelial activation have been described as risk
actors for adverse events in AF (3,4).
Whether inflammation and endothelial dysfunction are a cause
r a consequence of AF remains unknown. Development of CRP
evels after cardioversion of AF has shown controversial results,
nd data on evolution of inflammation after ablation are lacking.
This study investigated whether elimination of AF by ablation
ould influence the inflammatory state and endothelial dysfunction.
Fifty consecutive patients (49 males, 1 female; age 53  10
ears) referred for ablation of persistent or permanent drug-
efractory AF were studied. Five patients had long-lasting persis-
ent AF, defined as episodes lasting 7 days (mean 6 months,
ange 3 to 10 months). Forty-five patients suffered from perma-
ent AF, defined as AF that failed cardioversion or lasted for 1
ear. Atrial fibrillation was persisting for a median of 24 months
range 2 months to 20 years).
The ablation procedure was described in detail elsewhere (5).
ll patients underwent pulmonary vein isolation (PVI). Further
ubstrate modification consisted of linear lesions at the mitral
sthmus and at the roof of the left atrium. In patients with ongoing
F after PVI and linear ablation the following additional steps
ere performed: 1) energy applications at sites showing rapid or
eterogeneous activity for 90 to 120 s; 2) an intercaval line joining
he superior and inferior caval vein at their posterior aspect; and
) cardioversion.
A detailed data form including preclinical and procedural data
as completed for every patient. At the follow-up examinations
after 1 and 3 months) clinical symptoms were evaluated and
ransthoracic echocardiography and a 48-h electrocardiogram
ECG) performed. Follow-up blood samples were taken at the
-month follow-up. Patients suffering from any tachyarrhythmia
ymptoms or showing any atrial arrhythmia on 48-h ECG were
lassified as having recurrent arrhythmia. All antiarrhythmics
emained unchanged for at least 3 months after the index proce-
ure, as did all other medications, including anticoagulants,
eta-blockers, statins, angiotensin-converting enzyme (ACE) in-
ibitors and angiotensin (AT) II antagonists.
Plasma samples were frozen at 70°C and stored for further
xamination. All paired blood samples were analyzed on the same
ay to avoid calibration errors. High-sensitivity CRP (hsCRP) and
on Willebrand factor (vWf) activity were measured using com-
ercially available testing kits (hsCRP: BNII analyzer; Dade
ehring., Paris, France; vWf: Asserachrom vWf; Diagnosticahe hsCRP assay has a typical detection limit at 0.155 mg/l.
ormal activity for the Asserachrom vWf assay ranges from 50%
o 150%.
Fifteen patients (30%) suffered from structural heart disease.
ourteen patients were taking amiodarone at the time of the
rocedure, 11 patients were taking ACE inhibitors or AT II
ntagonists, 4 patients were taking statins, and 3 patients were
aking aspirin. Twenty-five patients were treated with beta-
lockers, which were stopped at least five half-lives before the
rocedure. Mean baseline hsCRP was 2.66 mg/l (range 0.155 to
3.9 mg/l), and mean vWf activity was 132 50%. There were no
ifferences in baseline characteristics for patients with successful
blation or failed maintenance of sinus rhythm 3 months after
blation (Table 1).
All patients underwent a single procedure after collection of
aseline data. At 3-month follow-up, 33 patients (66%) were free
f arrhythmia, 17 patients (34%) failed to maintain sinus rhythm,
2 suffered from paroxysmal AF, and 5 suffered from atrial
achycardia. Left atrial parasternal diameter decreased significantly
n the successfully treated group (45.8  5.6 mm vs. 42.6  4.8
m; p  0.003 by t test) but showed no change in the group with
ngoing arrhythmia (45.2 7.7 mm vs. 45.4 5.3 mm; p 0.9).
eft ventricular diameters and LVEF showed no difference before
nd after ablation in either group. Both groups had comparable
umulative radiofrequency energy delivery (87  32 min vs. 79 
0 min; p  0.5).
At baseline there was no difference in CRP between the
uccessfully treated patients and the patients with ongoing arrhyth-
ia (2.82  3.1 mg/l vs. 2.46  3.6 mg/l; p  0.32). At three
onths, CRP declined significantly in successfully treated patients
able 1. Baseline Patients Characteristics
Success
(n  33)
Failure
(n  17)
p
Value
ge (yrs) 53  10 54  10 0.7
F duration (months) 24 (3–96) 24 (12–60) 0.5
tructural heart disease 9 3 0.7
miodarone 9 5 0.9
tatin medication 2 2 0.6
spirin medication 2 1 0.6
igh-sensitivity CRP (mg/l) 2.82  3.1 2.46  3.6 0.3
Wf activity (%) 128  48 136  30 0.7
reatinine (mol/l) 92  12 94  16 0.7
eft atrial parasternal diameter (mm) 46  6 45  8 0.7
VEF (%) 65  11 62  11 0.5
adiofrequency duration (min) 87  32 79  30 0.5F  atrial fibrillation; CRP  C-reactive protein; vWf  von Willebrand factor;
VEF  left ventricular ejection fraction.
(
(
r
f
v
1
t
i
d
r
A
a
m
b
a
m
e
t
t
r
T
i
b
m
s
t
m
r
e
r
T
r
b
r
F
p y CR
p
1232 Correspondence JACC Vol. 47, No. 6, 2006
March 21, 2006:1226–382.82  3.1 mg/l vs. 1.37  1.3 mg/l; p  0.001 by paired t test)
Fig. 1A) but remained unchanged in patients with arrhythmia
ecurrence (2.46 3.6 mg/l vs. 2.58 3.4 mg/l; p 0.16) (Fig. 1B).
Neither at baseline nor at follow-up a difference could be shown
or vWf activity in the two groups (recurrence group: 136  30%
s. 140  26%; p  0.7; sinus rhythm group: 128  48% vs.
32  40%; p  0.7).
Subgroup analysis could not demonstrate any difference be-
ween CRP or vWf activity for patients with or without ACE
nhibitor treatment or for patients with or without structural heart
isease.
To our knowledge, this is the first study to demonstrate that
estoration of sinus rhythm in patients with long-lasting persistent
F leads to a decline in hsCRP. This finding was accompanied by
significant reduction in left atrial size. In patients who failed to
aintain sinus rhythm, no change in CRP or left atrial size could
e demonstrated. These findings suggest that atrial remodeling
nd modification of the inflammatory state are attributable to the
aintenance of sinus rhythm. In addition, this study assessed
igure 1. (A) Comparison of high-sensitivity C-reactive protein (CRP) v
atients that maintained sinus rhythm. (B) Comparison of high-sensitivit
atients that suffered from recurrent arrhythmia.ndothelial dysfunction by measuring vWf activity and showed nhat neither ablation nor the restoration of sinus rhythm influenced
his parameter.
Previous studies have shown that reverse atrial morphological
emodeling occurs after successful ablation of atrial fibrillation (6).
his remodeling process has been associated with parameters of
nflammation and the renin-angiotensin system (7,8), and it has
een suggested, in analogy to left ventricular remodeling, that
atrix metalloproteinases might be involved (9). Restoration of
inus rhythm decreases wall stress, resulting in a reduced activity of
he renin-angiotensin system. Consequently, stimulation of matrix
etalloproteinases and inflammation will be reduced; reverse
emodeling and a decline in inflammatory parameters will be the
ffect.
The cause-and-effect relationship between maintenance of sinus
hythm, atrial remodeling, and inflammation remains complex.
his study demonstrated that direct atrial tissue destruction by
adiofrequency current did not influence atrial size or inflammation
ut maintenance of sinus rhythm affected both parameters. The
elationship between atrial remodeling and inflammation however,
at baseline and 3 months after ablation, showing a significant decline in
P values at baseline and 3 months after ablation, showing no change inalueseeds to be further evaluated, as it remains unclear whether
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ersa.
Although this study did not include a control group, the levels
f CRP measured compare well to previously published data (1).
evels of CRP decreased after successful ablation to levels com-
arable with patients suffering from paroxysmal AF or patients in
inus rhythm at increased risk for AF. At that point, additional
harmacologic modification of the inflammatory state with an
CE inhibitor or a statin might be useful to reduce the risk of
rrhythmia recurrence (10).
Endothelial dysfunction is not influenced by ablation, restora-
ion of sinus rhythm, reverse remodeling, or a decline in inflam-
atory parameters. This finding confirms previous studies show-
ng sustained endothelial dysfunction despite a restoration of sinus
hythm by cardioversion (11), suggesting that endothelial dysfunc-
ion may not be maintained by AF.
In conclusion, we found that restoration of sinus rhythm by
blation leads to a decrease of the patient’s inflammatory state and
reverse remodeling of the left atrium.
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etters to the Editor
eft Ventricular Noncompaction,
ardiac Magnetic Resonance Imaging,
nd Neuromuscular Disorders
ith interest we read the report by Petersen et al. (1) concerning
ardiovascular magnetic resonance imaging (CMRI) in patients
ith left ventricular hypertrabeculation (LVHT), also termed
noncompaction.” Currently, several echocardiographic definitions
f LVHT exist, and up to now no CMRI-specific diagnostic
riteria for LVHT have been developed (2–4). We have, however,
oncerns and doubts as to whether the current study will clarify the
onfusion regarding the diagnosis of LVHT.
According to their definition, the investigators found by CMRI
hat “areas of non-compaction” were common in healthy volun-
eers, athletes, patients with hypertrophic or dilated cardiomyop-
thy, and aortic stenosis. Because these findings were not corre-
ated with echocardiographic or anatomic data, how can Petersen
t al. be sure that these areas were indeed “noncompacted” and not
ust the papillary muscles, false tendons, or aberrant bands, which
re common cardiac findings (5)?
When assessing the myocardial layers with different degrees of
issue compaction, how did the researchers differentiate myocar-
ium from flow artifacts? Why did they measure the ratio of
oncompacted/compacted myocardial layers in diastole and not in
ystole, as recommended by one of the echocardiographic defini-
ions (3)? How to explain the discrepancy between the relatively
mooth endocardial surface as seen on CMRI and the bizarre
orphology of trabeculations and deep intertrabecular recesses
hen examining LVHT patients echocardiographically and at
utopsy?
Echocardiography often does not visualize with clarity the left
entricular apex. Thus, we do not understand why this cardiac
egion, which can be much better visualized by CMRI than by
chocardiography, was excluded from measurements. According to
he investigators, a ratio of noncompacted to compacted myocar-
ial layers 2.3:1 in diastole distinguished “pathological” from
nonpathological” noncompaction. Why did they then diagnose
partial expression” of the disease in Patient #2, with a ratio of only
.1? What is the distinction between “nonpathological” noncom-
action and “partial expression” of noncompaction? According to
hich echocardiographic criteria was LVHT-diagnosed in the
even patients? Why were other family members of Patient #4,
